A55-22150-10480
1 vaccination
1 coded response
2 check-ins
1 free-text entry
1 call case
- Sex
- Female
- Age at first dose
- 26-30
- ZIP prefix
- 641 / MO
- Registered
- 2021-03-18
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-03-18
Registered in v-safe
-
2021-03-18
Dose 1 — Pfizer-BioNTech
-
2021-03-19
Health check-in — days 1–6 daily, dose 1Feeling: Fair · Site: Pain, Swelling · HeadacheAdult check-in
-
2021-03-20
Survey response — days 1–6 daily, dose 1MedDRA: Paranasal sinus hypersecretion — Feeling: Fair · Site: Pain, Swelling · Fever · Headache, Muscle or body aches, Fatigue or tiredness, Nausea · Be unable to do your normal daily activitiesFree text: Sinus drainageMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-03-20
Report sent to call center — days 1–6 daily, dose 1Be unable to do your normal daily activities1 call case(s)
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-03-18 | Pfizer-BioNTech |
Call center
1 call center case
1 priority 2/3 (triaged and no follow up)
Free text
Release 6 — days 1–6 daily, dose 1
Systemic reaction (other): Sinus drainage
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SRO | Paranasal sinus hypersecretion | ✓ | ✓ | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release